Answers are grounded in this paper and cite their sources.
Imatinib (IM) resistance is a major clinical challenge in treating gastrointestinal stromal tumors (GIST). This study aimed to investigate the effects and underlying mechanisms of Actinidia chinensis polysaccharide (ACPS) on IM resistance in GIST. The impacts of ACPS on the malignant behaviors of GIST were evaluated using the CCK-8 assay, Western blot analysis, colony formation assay, flow cytometry, wound-healing assay, and Transwell assay, combined with transcriptome sequencing and bioinformatic analysis. Clinical samples from GIST patients and matched adjacent non-tumor tissues were collected to detect the expression of nucleophosmin 1 (NPM1) at both cellular and tissue levels, and an orthotopic mouse tumor model was established to verify the in vitro findings. The results demonstrated that ACPS decreased the IC₅₀ value of IM-resistant GIST cells in a dose- and time-dependent manner, and significantly promoted apoptosis and suppressed cell proliferation and migration. Transcriptomic analysis and experimental validation revealed that NPM1 was abnormally overexpressed in IM-resistant GIST and promoted malignant progression. Mechanistically, ACPS blocked the PI3K/AKT signaling pathway by downregulating NPM1 expression, thereby effectively reversing IM resistance in vitro and suppressing the growth of IM-resistant GIST in vivo. This study reveals that ACPS can overcome IM resistance in GISTs by suppressing the NPM1–PI3K/AKT axis, providing a novel therapeutic strategy for the treatment of IM-resistant GIST.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: